Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures

Area of Science:

• Cardiovascular Pharmacology
• Neuroscience
• Endocrinology

Background:

• Insulin-induced severe hypoglycemia is a known risk factor for sudden death.
• Previous research indicated fatal cardiac arrhythmias as a primary mediator of this mortality.
• The roles of hypoglycemic seizures and the sympathoadrenergic system remained less understood.

Purpose of the Study:

• To investigate the contribution of hypoglycemic seizures and the sympathoadrenergic system to severe hypoglycemia-associated sudden death.
• To evaluate the efficacy of a combined pharmacological approach targeting both seizures and cardiac arrhythmias.

Main Methods:

• Adult Sprague-Dawley rats were subjected to hyperinsulinemic severe hypoglycemic clamps for 3.5 hours.
• Rats were randomized into four groups: saline, beta-1 blocker (atenolol), antiseizure (levetiracetam), or combination therapy.
• Cardiac function and seizure activity were monitored throughout the hypoglycemic period.

Main Results:

• Individual administration of atenolol reduced heart block, and levetiracetam reduced seizures, but neither prevented mortality.
• Combined treatment with atenolol and levetiracetam significantly reduced seizures and prevented respiratory arrest.
• The combination therapy also eliminated cardiac arrhythmias, resulting in 100% survival.

Conclusions:

• Severe hypoglycemia-induced sudden death involves distinct pathways: seizure-associated respiratory arrest and arrhythmia-associated cardiac arrest.
• Preventing both seizures and cardiac arrhythmias is crucial for mitigating mortality during severe hypoglycemia.
• Combined pharmacological intervention offers a promising strategy for preventing hypoglycemia-related sudden death.